EUCTR2013-004586-13-BE进行中（未招募）1 期
ong-term hepatitis A and B antibody persistence in healthy adult subjects, primed 16 to 20 years earlier with GSK Biologicals’ combined hepatitis A and B vaccine, Twinrix® (SB208127) in study HAB-084 (208127/084). - HAB-171 EXT 084 Y16-20
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
- •A male or female who received two/three doses of Twinrix according to his/her group allocation in study HAB-084 (208127/084), and received no further dose of any hepatitis A and/or B vaccine since then.
- •Written informed consent obtained from the subject.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 180
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within six months prior to study entry. Inhaled and topical steroids are allowed.
- •Administration of long-acting immune-modifying drugs within six months prior to the study entry.
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product (pharmaceutical product or device).
- •Administration of any hepatitis A and/or B vaccine at any time since completion of the primary vaccination series in HAB-084 (208127/084) study, including a challenge dose of the study vaccine, as a part of the study procedures, during the long-term persistence phase.
- •Documented history of hepatitis A or B disease since completion of the primary vaccination series in HAB-084 (208127/084) study.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •Administration of immunoglobulins within six months prior to study entry.
研究者
相似试验
进行中（未招募）
1 期
ong-term persistence of immunity to hepatitis B in adults vaccinated with GlaxoSmithKline (GSK) Biologicals’ hepatitis B vaccine (HBV), Engerix™-B.Healthy volunteers (immunisation against infection caused by all known subtypes of hepatitis B virus).MedDRA version: 19.0Level: PTClassification code 10019731Term: Hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-004099-31-BEGlaxosmithkline Biologicals100
进行中（未招募）
不适用
An open-label, phase IV, multicentre study to assess the long-term persistence of antibodies against hepatitis B and the immunogenicity and safety study of a single dose hepatitis B (Engerix™-B Kinder) vaccine challenge in adolescents aged 12-13 years, previously primed and boosted in the first two years of life with four doses of GSK Biologicals’ DTPa-HBV-IPV/Hib (Infanrix™ hexa) vaccine.Hepatitis BEUCTR2013-002821-41-DEGlaxoSmithKline Biologicals
进行中（未招募）
1 期
A study to evaluate persistence of hepatitis B antibodies, immunogenicity and safety of Engerix™-B Kinder challenge dose, in adolescents vaccinated with four doses of Infanrix™ hexa during infancy.Immunisation against infection caused by all known subtypes of hepatitis B virus.MedDRA version: 20.0Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-003391-74-DEGlaxoSmithKline Biologicals300
撤回
4 期
Evaluation of the Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix® (SB208127) in Study HAB-084 (208127/084)Hepatitis BHepatitis ANCT02135666GlaxoSmithKline
已完成
3 期
Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy AdultsHepatitis AHepatitis BNCT00289770GlaxoSmithKline50